Cardiovascular disease disparities: Racial/ethnic factors and potential solutions
- First Online:
- 149 Downloads
Disparities persist in cardiovascular disease, and it is difficult to separate socioeconomic status from race/ethnicity or genetic factors. Blacks have more hypertension, with higher cardiovascular morbidity and mortality. Despite high rates of type 2 diabetes and obesity, Hispanics do not appear to have higher cardiovascular mortality than non-Hispanic whites or blacks. South Asians have premature coronary heart disease, with more metabolic syndrome and diabetes. Racial/ethnic pharmacogenetics does not justify withholding appropriate medications. However, pharmacogenetics demonstrates the importance of using starting doses of medications that are ethnic specific. The Agency for Healthcare Research and Quality reports that the uninsured have difficulty accessing care, which may lead to delayed diagnosis and longer hospitalizations. Minority providers may positively affect the health of an increasingly diverse population.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.US Department of State: U.S. Minorities Will Be the Majority by 2042, Census Bureau Says. Available at http://www.america.gov/st/diversity-english/2008/August/20080815140005xlrennef0.1078106.html. Accessed March 12, 2009.
- 2.US Census Bureau: Population Projections: U.S. Interim Projections by Age, Sex, Race, and Hispanic Origin: 2000–2050. Available at http://www.census.gov/population/www/projections/usinterimproj. Accessed March 12, 2009.
- 3.Manchester J, Topoleski J: Growing Disparities in Life Expectancy. Economic and Budget Issue Brief. A Series of Issue Summaries from the Congressional Budget Office. Washington, DC: Congress of the United States; Congressional Budget Office; 2008.Google Scholar
- 4.Miniño, AM, Heron MP, Smith BL: Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006, 54:1–49.Google Scholar
- 5.US Census Bureau: The Face of Our Population. Available at http://factfinder.census.gov/jsp/saff/SAFFInfo.jsp?_pageId=tp9_race_ethnicity. Accessed March 12, 2009.
- 15.US Food and Drug Administration; Center for Drug Evaluation and Research: Coumadin labeling. New Labeling Information for Warfarin (marketed as Coumadin). Available at http://www.fda.gov/cder/drug/infopage/warfarin/default.htm. Accessed March 12, 2009.
- 16.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.CrossRefGoogle Scholar
- 17.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805–2816.CrossRefPubMedGoogle Scholar
- 19.US Food and Drug Administration; Center for Drug Evaluation and Research: Cozaar labeling. Available at http://www.fda.gov/cder/foi/label/2001/20386s26lbl.pdf. Accessed March 12, 2009.
- 29.McNamara DM, Tam SW, Sabolinski ML, et al.: G protein beta 3 subunit (GNB3) genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: fesults of the A-HeFT Trial [abstract 2174]. Circulation 2006, 114:II-442.Google Scholar
- 31.Centers for Disease Control and Prevention (CDC): Racial/ethnic and socioeconomic disparities in multiple risk factors for heart disease and stroke—United States, 2003. MMWR Morb Mortal Wkly Rep 2005, 54:113–117.Google Scholar
- 35.Agency for Healthcare Research and Quality: 2007 National Healthcare Quality Report. Rockville, MD: US Department of Health and Human Services; Agency for Healthcare Research and Quality; 2008. [AHRQ publication no. 08-0040.]Google Scholar
- 36.Agency for Healthcare Research and Quality: 2007 National Healthcare Disparities Report. Rockville, MD: US Department of Health and Human Services; Agency for Healthcare Research and Quality; 2008. [AHRQ publication no. 08-0041.]Google Scholar
- 37.Centers for Disease Control and Prevention (CDC): Cigarette smoking among adults—United States, 2007. MMWR Morb Mortal Wkly Rep 2008, 57:1221–1226.Google Scholar
- 40.US Department of Health and Human Services: Eliminating Health Disparities: Strengthening Data on Race, Ethnicity, and Primary Language in the United States. Available at http://www.cdc.gov/nchs/data/misc/EliHealthDisp.pdf. Accessed March 12, 2009.
- 43.Jacoby MB, Sullivan TA, Warren E: Medical problems and bankruptcy filings. Norton’s Bankruptcy Law Adviser. May 2000. Cited in: Institute of Medicine, Committee on the Consequences of Uninsurance: Insuring America’s Health: Principles and Recommendations. Washington, DC: National Academy Press; 2004.Google Scholar
- 44.Kaisernetwork.org: Kaiser Health Disparities Report: A Weekly Look at Race, Ethnicity and Health. Available at http://www.kaisernetwork.org/DAILY_REPORTS/rep_index.cfm?DR_ID=54193. Accessed March 12, 2009.
- 45.US Department of Health and Human Services: Healthy People 2010. Leading Health Indicators. Available at http://www.healthypeople.gov/LHI. Accessed March 12, 2009.
- 46.Nielsen-Bohlman L, Panzer AM, Kindid DA: Health Literacy: A Prescription to End Confusion. Washington, DC: National Academy Press; 2004.Google Scholar
- 47.US Department of Health and Human Services; Office of Minority Health: Think Cultural Health: Bridging the Health Care Gap Through Cultural Competency Continuing Education Programs. Available at http://www.thinkculturalhealth.org/. Accessed March 12, 2009.
- 51.Institute of Medicine Committee on Quality of Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington DC: National Academy Press; 2001.Google Scholar